The expression of MMP-1, -2, -9 and TIMP-1 was studied in 10 benign cartilage-forming osteal tumors (5 osteochondromas and 5 chondromas) and 39 chondrosarcomas (14 central, 4 periosteal, 7 dedifferentiated, and 14 secondary tumors). No expression of MMP and TIMP-1 was detected in benign cartilage-forming osteal tumors. In chondrosarcomas, the expression of MMP-1 was detected in 84.6%, of MMP-2 in 71.8, of MMP-9 in 97.4, and of TIMP-1 in 82.4% cases, the levels of expression of these markers varied from 10 to 60%. The expression of MMP-1 was not associated with patient gender, maximum size and degree of differentiation of the tumor, but was linked with age. The expression of MMP-1 was more often detected in central and dedifferentiated chondrosarcomas; the expression of MMP-1(+) was significantly associated with 3-year relapse-free and 5-year overall survival of the patients. The expression of MMP-1 in the tumor was associated with unfavorable course of the disease. The values of MMP-2 expression in chondrosarcomas did not reflect the main clinical morphological characteristics of the disease and its prognosis. The level of MMP-9 protein expression in chondrosarcomas ≥40% is prognostically unfavorable, while <40% is a favorable factor for 3-year relapse-free survival. The risk of disease relapse within 1 year after the beginning of therapy was maximum in T3 tumors with expression of MMP-9 protein ≥40%. No relationships between the parameters of TIMP-1 expression in chondrosarcomas and the main clinical morphological characteristics of the disease and its prognosis were detected.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
N. V. Zhukov and S. A. Tyulyandin, Biokhimiya, 73, No. 5, 751–768 (2008).
N. E. Kushlinskii, Yu. N. Solovyov, I. V. Babkina, et al., Byull. Eksp. Biol. Med., 149, No. 2, 194–196 (2010).
G. A. Frank, L. E. Zavalishina, and Yu. Yu. Andreeva, Precise Diagnosis of Cancer by Immunohistochemical Evaluation of Markers [in Russian], Moscow, P. A. Hertzen Oncological Institute (2009), p. 12.
K. R. Berend, A. P. Toth, J. M. Harrelson, et al., J. Bone Joint. Surg., 80-A, No. 1, 11–17 (1998).
Y. J. Chen, Y. Y. Wei, H. T. Chen, et al., J. Cell Physiol., 221, No. 1, 98–108 (2009).
Y. A. De Clerck, H. Shimada, S. M. Taylor, et al., Ann. N. Y. Acad. Sci., 732, 222–232 (1994).
E. I. Deryugina and J. P. Quigley, Cancer Met. Rev., 25, No. 1, 9–34 (2006).
A. L. Folpe and C. Y. Inwards, Bone and Soft Tissue Pathology (A Volume in the Series Foundations in Diagnostic Pathology. Series Ed.: J. R. Goldblum), Philadelphia (2010).
A. R. Nelson, B. Fingleton, M. L. Rothenberg, et al., J. Clin. Oncol., 18, No. 5, 1135–1149 (2000).
L. B. Rozeman, A. M. Cleton-Jansen, and P. C. Hogendoorn, Int. Orthop., 30, No. 6, 437–444 (2006).
L. L. Wang, Cancer J., 11, No. 4, 294–305 (2005).
J. Westermarck and V. M. Kahari, FASEB J., 13, No. 8, 781–792 (1999).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 149, No. 3, pp. 317–322, March, 2010
Rights and permissions
About this article
Cite this article
Boulytcheva, I.V., Kushlinskii, N.E., Dvorova, E.K. et al. Expression of Matrix Metalloproteinases 1, 2, 9 and Their Tissue Inhibitor-1 in Cartilage-Forming Osteal Tumors. Bull Exp Biol Med 149, 341–346 (2010). https://doi.org/10.1007/s10517-010-0942-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-010-0942-z